Aethlon Medical (NASDAQ:AEMD)expanded executive team with two key appointments: Guy Cipriani as SVP & Chief Business Officer, and Steven LaRosa, M.D., as Chief Medical Officer.

Aethlon Medical (NASDAQ:AEMD)扩大了高管团队，任命了两名关键人员:盖伊·奇普里亚尼(Guy Cipriani)担任高级副总裁兼首席业务官，史蒂芬·拉罗萨(Steven LaRosa)医学博士担任首席医疗官。

In his new role, Mr. Cipriani will oversee business development and partnerships, while also contributing to fundraising and corporate development.

在他的新职位上，奇普里亚尼将负责业务发展和伙伴关系，同时也为融资和企业发展做出贡献。

Dr. LaRosa will be responsible for the clinical development of Aethlon's Hemopurifier, including leading clinical operations and regulatory strategy.

拉罗萨博士将负责Aethlon血液净化器的临床开发，包括领先的临床操作和调控策略。

Most recently, Mr. Cipriani served as the Chief Business Officer at Microbion, company focused on the development of a new class of antibiotic therapies for difficult to treat and resistant infections.

最近，他曾担任Microbion的首席商务官，该公司专注于开发一种新型抗生素疗法，用于治疗难治和耐药感染。

Dr. LaRosa most recently served as VP, Clinical Development of Entasis Therapeutics, a spin-out of AstraZeneca focused on pathogen-targeted small molecules to treat serious multidrug-resistant Gram-negative infections.

他最近担任Entasis Therapeutics的副总裁，负责临床开发，这是阿斯利康(AstraZeneca)的子公司，专注于病原体靶向小分子治疗严重的多药耐药革兰氏阴性感染。

Shares trading 5% down premarket.

股票交易前下跌了5%。